# Presentation: 604613

## Review of R21s in CSR(Part II)Elaine Sierra-Rivera, PhDScientific Review AdministratorOncological Sciences IRGDBBDCenter for Scientific Review

## What are R21’s

**Mechanism to allow PIs to conduct define research on innovative ideas, develop new concepts or techniques**
**Awards vary by IC and purpose of initiative **
**Lead to a larger research grant (e.g. R01, P01, etc.)**
**Must be submitted in response to a PA       (PI initiated — ****PA-06-181****)**** **
**~214 Currently Active PAs**

## Other Characteristics of R21s

**Modular Budget (Range of 75 – 175K/year)**
**Award could last from one to five years (but generally last two years)**
**15 Page Research Plan (Few exceptions)**
**Allow up to 2 revisions/amendments**** **
**Preliminary data not required **
**No competing continuations**
**Appendix (PA specific)**
**SF424 – June 1, 2006 all electronic submission**

## Outcome of Electronic R21 Applications Submission Process

**3,474 Applications Assigned to Review Groups**
**472 (14%) Will be Review by IC’s**
**2,898 (86%) Will be Review by CSR**
**805 (13.2%) ******** A1**
**191 (5.5%) ******** A2**
**1,616 (48%) New PI (****√ Face Page)**

## Findings from Data Presented  PRAC Meeting – May 2006

**No difference in the streamlining (UN) or scoring pattern of R21 applications compared to R01 applications, when evaluated in the context of review environment **

## Effect of Review Environment

**    ****PERCENT**

**R21 =  8,579           R01 = 23,445 **

**   **_**<**_**150              151 - 175    176 – 200     >201               UN**

## Questions Generated from Data

**Are R21s streamlined at a higher rate than R01s?**
**Are there scoring discrepancies among study sections?**
**Is the R21 mechanism being used for its intended purpose?**

## Review Guidelines Provided to Reviewers

- 	“The R21 mechanism is designed to support exploratory or developmental research R21 allowing investigators to conduct research on innovative ideas or develop new concepts or technologies.  R21 applications generally can only be submitted in response to a specific NIH initiative.  Each initiative has its own unique features and often unique review criteria.  **Final scores must reflect the scientific and technical merits of the application rather than whether the proposed studies meet the goals of the PA.**  Maximum duration of award varies by announcement from one to five years, but generally R21s are for two years duration.  Budgets can also vary, but are typically between $75,000 to $150,000 per year, and thus follow the modular budget requirements.  **Reviewers must keep in mind that PAs cover a variety of goals. For example, some support high impact-high risk investigations, some support exploratory non-hypothesis driven studies, and some support the development of techniques**.  Applications must be evaluated in the context of the PA goals. Therefore, before initiating your review of an R21 grant application, the reading of the specific announcement is necessary”
- 	**“****Reviewers must keep in mind that Preliminary Data are not required for the R21 mechanism. Although any preliminary data provided should be evaluated, no new data should be requested. Applications should not be penalized for lacking preliminary data****”**

## Further Analysis (Data obtained from 10 - 2005 to 5 - 2006 Review Cycles)

**R21 Applications have been grouped according to type (goals) of PAs ****(applications are not limited to High-Risk/High-Gain studies)**
**Analysis limited to Type 1 applications**
**A sample of Chartered Study Sections (representing all IRG’s) have been included in the analyses **

## Unscoring Pattern for R21 Applications Reviewed in Chartered Study Sections with <40% R21/R03

## Unscoring Pattern for R21 Applications Reviewed in Chartered Study Sections with >40% R21/R03

## Percent R21 Unscored Applications per PA Group/Classification (Total R21= 5,161)

**                   **** ****PERCENT**

** ****197**

**794**

** ****3,075**

**399**

**66**

**122**

**396**

** ****55**

**  ****57**

## Parent PA (PI Initiated) Total R21 = 2,132

**	****Sample Study Sections**

**     ****  ****PERCENT**

**                ****46    41    51    12     41     51    40     46    11     18   ****** **R21**
**              ****133    166   127  85   174   205   209  104   148   101** **** **R01**

## Overall Scores for R21s Reviewed at Chartered Study Sections

**Overall Scores for R21s Reviewed at Chartered Study Sections**
**                                         ****Total R21 = 5,161**

## SUMMARY

**R21s are not differentially unscored compared to R01s**
**R21 Application Scores are comparable to Type 1 R01s**
**Study Sections are following review characteristics specific to R21 applications, reflecting SRAs effort in properly orienting reviewers to the uniqueness of this mechanism**

## Acknowledgements

**Teresa Lindquist,**** ****Program Analyst ****Office of Planning, Evaluation and Analysis, CSR **** **
**Valerie L. Durrant,****  ****Scientific Review Administrator, Health of the Population (HOP) Integrated Review Group**
**Laura Roman,**** ****Assistant Director- DRR/CSR**
**Michael Martin,**** ****Division Director - DPP****   **
**Cheryl Kitt,**** ****Deputy Director - CSR****  **

## Innovative Research -To Attract New PI(Total R21 = 197)

**                    ****PERCENT**

**Sample Study Sections**

**R21 ********  14        28      24        28        34        6         3**
**R01 ********   285        109      104      131    156       148    230**

## Innovative Studies (Total R21 = 122)

**     **

**  **

**         ****PERCENT**

**   ****R21******** 25       34       17      12      2          1       16        3**
**   ****R01******** 140    278     188     233    220    166    73     246**

**Sample Study Sections**

-  1

## Diagnosis & Pre-Clinical Development(Total R21= 396)

** **

**             ****PERCENT**

**      ****R21********   30       23        56       13        17      18           21**
**      ****R01********  127    162      174      201     199    133        144**

**Sample Study Sections**

## High Impact-High Risk/Innovative(Total R21 = 794)

**      **

**          ****PERCENT**

**R21******** 40      10      43     49      57    7     30     5        3**
**R01******** 86     140    131   54      237  89     133  169   241**

**Sample Study Sections**

- 1

## Basic/Non-Hypothesis Driven (Total R21 = 55)

**       **

**Sample Study Sections**

**PERCENT**

**R21********  6            4              17            3         9          2**
**R01********  166       191          148         238      153       169**

## Biodefense (Total R21 = 399)

**Sample Study Sections**

**                 ****PERCENT**

** ****R21******** 56         48       29        17         14     11         12**
** ****R01********138      163     157      201        88       101     127**